Current Report
Filed: 2026-04-07
Key Insights
- Supernus Pharmaceuticals has agreed to acquire the assets related to the compound NV-5138 or SPN-820 from Navitor Pharmaceuticals through an asset purchase agreement.
- The agreement includes milestone payments of up to $350 million contingent upon the achievement of specified development, regulatory and commercial milestones for the acquired compound.
- The company has the right to discontinue the development of the compound after the completion of the Phase 2b study if it determines the study was not successful.